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Malaria is a global public health challenge, with drug resistance a major barrier to disease control and elimination.
To meet the urgent need for better treatments and vaccines, a deeper knowledge of Plasmodium biology and
malaria epidemiology is required. An improved understanding of the genomic variation of malaria parasites, espe-
cially the most virulent Plasmodium falciparum (Pf) species, has the potential to yield new insights in these areas.
High-throughput sequencing and genotyping is generating large amounts of genomic data across multiple parasite
populations. The resulting ability to identify informative variants, particularly single-nucleotide polymorphisms
(SNPs), will lead to the discovery of intra- and inter-population differences and thus enable the development of
genetic barcodes for diagnostic assays and clinical studies. Knowledge of genetic variability underlying drug resis-
tance and other differential phenotypes will also facilitate the identiﬁcation of novel mutations and contribute to
surveillance and stratiﬁed medicine applications. The PlasmoView interactive web-browsing tool enables the re-
search community to visualise genomic variation and annotation (eg, biological function) in a geographic setting.
The ﬁrst release contains over 600 000 high-quality SNPs in 631 Pf isolates from laboratory strains and four
malaria-endemic regions (West Africa, East Africa, Southeast Asia and Oceania).
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Malaria parasites cause disease in approximately 650
million people and Plasmodium falciparum (Pf) in
particular kills up to 1 million people each year [1]. Anti-
malarial drug resistance is a major public health problem
that hinders disease control and elimination efforts [2]. Pf
parasites from almost all malaria-endemic countries show
modest levels of drug resistance, especially to chloroquine
[3]. Recent evidence indicates that Pf parasites in Cambo-
dia and Thailand are developing resistance to artemisinin
– currently the most effective anti-malaria intervention
[4–7]. An improved understanding of Pf genetics has pro-
vided new insights into the molecular mechanisms of
drug resistance [8–10] and may ultimately lead to new
treatments and reduce the global disease burden [11].
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High-throughput sequencing technologies and large-scale
genotyping chips are generating genome-wide Pf data on an
unprecedented scale. This means that it is now possible to
densely map genomic variation (eg, single-nucleotide polymor-
phisms, SNPs) and assess global diversity. Knowledge of the di-
versity of variants across populations will enable the biological
interrogation of novel mutations and identiﬁcation of candidate
vaccines. Other potential applications include SNP-based
assays to barcode parasites over time and space for epidemio-
logical, diagnostic and clinical studies. However there are
several roadblocks to the translation of genomic variation into
useful public health tools. These include difﬁculties in obtain-
ing robust phenotypic data (eg, drug resistance and mosquito
transmission) on samples and the lack of web-based informat-
ics tools to access robust genomic data, which are needed to
launch further experiments and translational activities.
Whilst the plasmodDB [12] and genedb [13] web-browsers
provide genomic annotation and support the investigation of
SNPs in individual parasite strains, there is a need for addition-
al information (eg, allele frequencies and population statistics)
across the growing collection of publicly available sequences
and genotypes from clinical Pf isolates. We are making avail-
able to the malaria community the PlasmoView web-browser
(http://pathogenseq.lshtm.ac.uk/plasmoview) to facilitate the
investigation of genome-wide polymorphisms in parasites from
different malaria-endemic regions.
RESULTS
SNP Data
We aligned raw sequence and genotyping data (to the 3D7
reference genome, version 3, 80.9% AT, 23 Mb, 14 chromo-
somes) from 971 Pf samples from four regions: West Africa
(WAF, Burkina Faso, Gambia, Ghana, Mali and Senegal),
East Africa (EAF, Kenya and Malawi), Southeast Asia (SEA,
Cambodia, Thailand and Vietnam) and Oceania (OCE,
Papua New Guinea, Supplementary Table S1). After quality
control procedures, 631 samples (8 laboratory/reference, 367
WAF, 88 EAF, 151 SEA and 17 OCE) were retained. The
alignments and high coverage (>10-fold) enabled the identiﬁ-
cation of 593 579 (2.6% of all nucleotides) high-quality SNPs
across the nuclear genome (51% exonic, 33% non-synony-
mous, Supplementary Figure 1A). These SNPs include the
86 158 SNPs identiﬁed in 227 samples [14]. Seventy-three
per cent (434 290) of SNPs are rare (minor allele frequency,
MAF < 1%) and 4% (29 036) are common (MAF > 10%, see
Supplementary Figure 1B).
The linkage disequilibrium between non-rare markers
reveals decay with physical genetic distance (Supplementary
Figure 1C). This decay is higher in the African regions (WAF
and EAF) than in SEA or OCE. As expected, a principal com-
ponent analysis reveals that the SNP data differentiate the
samples by geographic region (Supplementary Figure 1D) and
population (not shown). To identify the polymorphisms
driving the population differentiation, we applied a SNP-wise
FST approach where values between 0 and 1, higher values
imply more differentiation [15]. The application across regions
identiﬁes 467 SNPs with FST > 0.1 indicating a high level of
regional differentiation. As expected, the FST values of intra-
region comparisons are substantially lower (% SNPs with FST-
> 0.1: WAF 0.2%, EAF 1.6%, SEA 6.6% and OCE n/a) than
inter-region comparisons (% SNPs with FST > 0.1: 27.9%) in
common SNPs (MAF > 15%).
PlasmoView
The web-based PlasmoView tool presents genome-wide varia-
tion and geographical information on Pf. The implementation
contains a ﬁrst release of over 370 million data points (approxi-
mately 600 k SNPs in over 600 samples described above). Plas-
moView provides real-time visualisation and summary statistics
and is a timely tool for the high-level interrogation of large
genomic datasets. Pf data are presented in two views: (a) the
matrix view provides a colour-coded indication of mutation lo-
cations ordered by genetic and geographical location; and (b)
the map view shows a global view of SNP prevalence by
country. The matrix view includes graphical and real-time
textual SNP-by-SNP genomic annotation (reference alleles,
subtelomeric regions, gene regions, amino acid changes and
genomic uniqueness) as well as MAF and FST graphs plotted
for the selected data. Both matrix and map views are interactive
enabling researchers to easily navigate the data via the menu at
the top of the application or using mouse buttons. The Plasmo-
View launch page includes a facility to search by common gene
name (eg, RH5 or CRT), previous id (PFD1145c orMAL7P1.27)
and the latest gene nomenclature (PF3D7_0424100 or PF3D7_
0709000). The tool is scalable for the signiﬁcant increase in
data that is anticipated over the next few years. In the next sec-
tions we demonstrate the utility of PlasmoView using speciﬁc
loci in the Pf genome.
Drug resistance in Pf is commonly due to SNPs in genes in-
volved in the biological pathways that antimalarials target. The
matrix view in PlasmoView is ideally suited to display all ob-
served mutations on a gene-by-gene basis. Figure 1 shows the
mutations for each sample in PfCRT (PF3D7_0709000), a gene
on chromosome 7 associated with chloroquine resistance [16].
Sixty-one SNPs (18 non-synonymous) have been detected in
this gene, 5 of which are known to be involved in drug resis-
tance. The high regional differentiation is measured by the
SNP-wise FST (maximum 0.63, see blue histogram track in
Figure 1). In PlasmoView the geographic spread of any muta-
tion is further visualised in the map view, which displays SNP
frequencies by geographical location. For example, Figure 2
shows the frequency of mutations observed across samples
from each country at chromosome 7, position 403 615 (the
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Figure 1. Global mutations in the Pf chloroquine resistance transporter gene (PfCRT). The 61 SNPs (18 non-synonymous) identiﬁed in PfCRT (Chromo-
some 7, PF3D7_0709000) are shown. Some markers (eg, Q271E) show evidence that they have gone to ﬁxation in SEA (blue on the left axis) and are
common throughout the rest of the world (WAF: green; EAF: yellow; OCE: purple on the left axis). Six known drug resistance markers are shown, as well as
3 common SNPs located in intronic regions (IT).
Figure 2. Global distribution of the resistance-conferring PfCRT mutation K76T. The global prevalence of the K76T mutation (Chromosome 7, position
403 615) can be seen with the mutation ﬁxed or close to ﬁxed in most countries. Parasites may have reverted back to the wildtype allele, due to the com-
plete withdrawal of chloroquine from some countries (eg, in East Africa, yellow on the left axis). The LAB Pf strains (laboratory-adapted and imported Pf
strains) are located over the South Atlantic. Information on each bar chart is available by holding the cursor over it.
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PfCRT K76T amino acid mutation, [17, 18]). PlasmoView
enables the easy identiﬁcation of mutation sites within each
gene, estimate their allele frequencies and investigate their geo-
graphical context, via the matrix view, the AF and FST graphs
and the map view, respectively. The matrix views for three
other genes (PfDHFR, PfDHPS and PfMDR1) involved in drug
resistance are presented in Supplementary Figures 2A–C and
also provided as part of the set of pre-loaded examples of inter-
est for the web-browser.
Whilst a number of SNPs within drug resistance loci have
been well characterised, other more recent and important
regions may require investigation. For example, a major region
of chromosome 13 (1.73 Mb to 1.82 Mb) in the Pf genome was
identiﬁed to be undergoing a selective sweep due to artemisinin
resistance in Southeast Asia [8]. It is possible to visualise the
SNP variations in this region for all 631 global parasite isolates
and laboratory-adapted parasite strains. The SNP density is
very high in this region (1355 SNPs in 50 kb, 1.77 Mb to 1.82
Mb, Figure 3), so we use the SNP-by-SNP information to direct
further investigation. There are interesting SNPs progressing to
ﬁxation (high MAF and low FST) and those showing large geo-
graphical differences (high FST). For example, the SNP at posi-
tion 1 793 121 in Pf3D7_1344700 (Supplementary Figures 2D
and E, MAF 17%, FST 0.38) has been identiﬁed as having the
highest association with parasite clearance rate [[8], denoted
SNP 1]. PlasmoView shows 46 SNPs in this region whose FST is
greater than 0.1 including 14 non-synonymous SNPs and one
synonymous in PF3D7_1343800 (22 785 bp, 591 SNPs) and
four non-synonymous SNPs and one synonymous SNP in
PF3D7_1344300 (4768 bp, 132 SNPs).
The lack of an effective licensed vaccine remains one of the
most signiﬁcant gaps in the arsenal to control and eliminate Pf
malaria [19]. The Pf Reticulocyte Binding Protein Homologue
5 (encoded by the PfRH5 gene, PF3D7_0424100) is considered
a promising candidate antigen, as it seems to be essential for
the invasion of multiple laboratory-adapted Pf lines and clinical
Pf isolates into red blood cells [19]. High genetic variation in
target genes can pose difﬁculties in the design of a vaccine that
covers the full range of diversity across populations. The diver-
sity observed for PfRH5 across 227 clinical Pf isolates was low,
with only 5 non-synonymous SNPs (out of 12) reaching a fre-
quency greater than 10% in at least 1 population [19]. Using
PlasmoView to analyze more than double the number of
samples and 5 additional populations, we identify 22 non-
synonymous SNPs (out of 28) and conﬁrm the locus has low
diversity (Figure 4) with only 5 SNPs exhibiting a frequency
greater than 10%.
Detecting balancing selection is one method to identify sig-
natures of acquired immunity and therefore potential targets
for vaccines. As immunity to the commonest alleles rises in
malaria-endemic areas, parasites expressing rarer alleles experi-
ence a selective advantage. This process maintains a balance of
alleles in the population, with neither the common alleles
moving to ﬁxation nor the rare alleles moving to extinction.
When multiple alleles are maintained within populations and
none of them achieves ﬁxation, balancing selection forces are
believed to be present. In PlasmoView, loci under balancing se-
lection are readily be visualised as SNPs with intermediate
MAF (10% to 40%) and low FST (indicating little population
differentiation). These signatures are shown in vaccine targets
previously identiﬁed using methods to detect balancing selec-
tion, including the MSP3.8 (merozoite surface protein 3.8,
PF3D7_1036300, Supplementary Figure 2F) and AMA1 (apical
membrane antigen 1, PF3D7_1133400) genes [11, 20, 21]. The
malaria vaccine FMP2.1/AS02A is a recombinant protein
(FMP2.1) based on AMA1 and has been tested in clinical trials
[22], see Figure 5.
The Pf mitochondrial genome (Pf_M76611, 6 kb, 3 genes
(Cox3, Cox1, CytB), GC content 31.6%) is uniparentally inherit-
ed and does not undergo recombination. Therefore mitochon-
drial DNA (mt) sequence divergence and variation data have
been used to study the evolutionary history and migration of Pf
[23–25], particularly gene ﬂow out of Africa. Analyses of the
global patterns ofmt sequence variation have revealed geograph-
ic differentiation [24–26]. PlasmoView shows 85 SNPs, including
the three SNPs with MAF greater than 5% and FST in excess of
0.05 (mt772, mt1692 and mt1776, see Figure 6), which have pre-
viously been utilised in diversity studies [23, 24, 26]. We do not
observe a mutation at amino acid position 268 in CytB (cyto-
chrome B, cob, MAL_MITO_3:4293) that had been correlated to
atovaquone resistance following treatment failure [25].
DISCUSSION
The continued public health burden of malaria and emergence
of drug resistance requires the development of new treatments,
vaccines and control measures. These efforts are likely to
beneﬁt from a deeper understanding of Pf biology and malaria
epidemiology, in part deriving from analysis of parasite genetic
variation. New genomic approaches, using massively parallelis-
able sequencing and genotyping technologies, are generating
vast amounts of Pf genetic data. However, to fully achieve their
scientiﬁc potential, including the initiation of further experi-
ments and translational activities, web-based informatics tools
are needed to help researchers to access this genomic informa-
tion. The PlasmoView web-browser condenses and summarises
SNP information derived from these technologies into a shared
and interpretable visual form. The ﬁrst release contains nearly
600 k SNPs in over 600 samples that have gone through the
same high-quality control procedures as previous studies [14,
27, 28], with additional validation using clonal samples that un-
derwent both sequencing and genotyping. Genome annotation
and measures of quality control (eg, uniqueness) incorporated
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Figure 3. Pf chromosome 13, 1770 kb to 1820 kb. Cheeseman et al [8] described this region as being potentially important to the evolution of artemisi-
nin-resistant Pf parasites in Southeast Asia. Of the 1355 SNPs in this 50-kb region, more than 20 exhibit high regional speciﬁcity (predominantly in SEA
with high FST (>0.1) and low MAF (<30%)) and at least 10 may have spread or are currently spreading to other regions (high MAF and low FST). Gene
Pf3D7_1344700 (see Supplementary Figure 2D) contains an example of both: a SNP with high regional speciﬁcity (position 1 793 121, labelled as SNP 1 in
[8], Supplementary Figure 2E ) and one moving towards global ﬁxation (position 1 794 574).
Figure 4. PfRH5 vaccine candidate in chromosome 4. The Pf Reticulocyte Binding Protein Homologue 5 (PfRH5, PF3D7_0424100) gene is considered a
promising vaccine candidate, as it seems to be essential for blood-stage parasite invasion of red blood cells [20]. The locus contains 28 SNPs, including 5
non-synonymous mutations with MAF >10% (I410M, S197Y, H148D, Y147H [19] and K419N [20]).
1812 • JID 2014:209 (1 June) • Preston et al
 at London School of H
ygiene &
 Tropical M
edicine on M
arch 17, 2015
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Figure 5. AMA1 vaccine candidate in chromosome 11. The apical membrane antigen 1 gene (AMA1, Chromosome 11, PF3D7_1133400) has long been
recognised as a vaccine candidate and is currently being evaluated in clinical trials [22]. The high number of SNPs with intermediate MAF and low FST indi-
cate that this locus is under balancing selection.
Figure 6. Mitochondrial genome. The Pf mitochondrion is a small, uniparentally inherited organelle and its DNA (6 kb) is used for investigating Pf evolu-
tion and migration [23, 24, 26]. Six SNPs exhibit population differentiation (FST > 0.05; mt74, mt772, mt1692, mt1776, mt2383 and mt2641) including three
common alleles (MAF > 5%; mt772, mt1692 and mt1776) used to support an African origin for the species [24, 26].
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into the tool allow a further level of assessment of variant
quality. The ultimate validation is likely to come from indepen-
dent studies using whole-genome sequencing technologies.
When these data are placed into the public domain with appro-
priate meta-data (eg, location of samples) then these raw se-
quence data will be processed using our proven pipeline and
included in PlasmoView.
The case studies above demonstrate the utility of PlasmoView
to support informed decision-making processes, whether they
take place in the clinic, laboratory or public policy arena. The
genomic variation identiﬁed in drug resistance (eg, PfCRT,
PfDHFR and PfMDR1) and vaccine candidate (eg, PfRH5,
MSP3.8 and AMA1) genes will help to deﬁne the potential rep-
ertoire of polymorphisms for follow-up experiments. Similarly,
the identiﬁcation of polymorphisms that drive genetic differen-
tiation at the continental, regional and village level (eg, in drug
resistance and surﬁn genes) will facilitate the barcoding of para-
sites for use in surveillance applications. PlasmoView has the
functionality to display the variation with annotations, geo-
graphical distribution and frequency data and population dif-
ferentiation metrics in real time.
Whilst PlasmoView is presented as a tool to visualise and sum-
marise Pf variation, it will be extended to other Plasmodium
species as the data becomes available. The next phase of the work
is to characterise and display variation other than SNPs, leverag-
ing off the high-coverage, paired-end nature of sequence data
[29] and results from genotyping approaches (eg, comparative
genomic hybridization [30]). Functionality will expand to include
additional population genetic statistics (eg, Tajima’s D [31]).
In summary, PlasmoView is a powerful, scalable tool for the
interactive geographic visualisation of Pf mutations. Using a
high-quality set of polymorphisms, this study shows that Plas-
moView is useful in conﬁrming existing results, identifying po-
tential avenues for further research and presenting complex
genetic data to a broad audience.
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